Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-10-10
2006-10-10
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S229100, C424S230100, C424S231100, C424S281100, C424S093200
Reexamination Certificate
active
07118755
ABSTRACT:
An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response when dendritic cells are infected with the virus.
REFERENCES:
patent: 5998174 (1999-12-01), Glorioso et al.
patent: 6641817 (2003-11-01), Coffin et al.
patent: 6713067 (2004-03-01), Coffin
patent: WO 97/13866 (1997-04-01), None
patent: WO 98/04726 (1998-02-01), None
patent: WO 98/30707 (1998-07-01), None
patent: WO 98/51809 (1998-11-01), None
patent: WO 99/60145 (1999-11-01), None
patent: WO 00/08191 (2000-02-01), None
Krisky et al (Gene Therapy 5:1517-1530, 1998).
Gough et al. “Expression of The Hepatitis B Virus Surface, Core and E Antigen Genes by Stable Rat and Mouse Cell Lines” J. Mol. Biol. 162:43-67 (1982).
Huard et al. Neuromuscular Disorders 7:299-313 (1997) (Abstract only cited).
Inaba et al. “Identification of Proliferating Dendritic Cell Precursors in Mouse Blood” J. Exp. Med. 175:1157-1167 (1992).
Jones et al. “Mutational Analysis of theHerpes simplexVirus Virion Host Shutoff Protein: Evidence That vhs Functions In The Absence of Other Viral Proteins” J. of Virol. 69:4863-4871 (1995).
Kruse et al. “Mature Dendritic Cells Infected withHerpes simplexVirus Type 1 Exhibit Inhibited T-Cell Stimulatory Capacity” J. of Virol. 74:7127-7136 (2000).
Lokensgard et al. “Long-Term Promoter Activity DuringHerpes simplexVirus Latency” J. of Virol. 68:7148-7158 (1994).
MacLean et al. “Herpes simplexVirus Type 1 Deletion Variants 1714 and 1716 Pinpoint Neurovirulence-Related Sequences in Glasgow Strain 17 Between Immdiate Early Gene 1 and The ‘a’ Sequence” J. of Gen. Virol. 72:631-639 (1991).
MacLean et al. “Investigation ofHerpes simplexVirus Type 1 Genes Encoding Multiply Inserted Membrane Proteins” J. of Gen. Virol. 72:897-906 (1991).
McFarlane et al. “Hexamethylene Bisacetamide StimulatesHerpes simplexVirus Immediate Early Gene Expression in The Absence of Trans-Induction by Vmw65” J. of Gen. Virol. 73:285-292 (1992).
Reeves et al. “Retroviral Transduction of Human Dendritic Cells With A Tumor-Associated Antigen Gene” Cancer Research 56:5672-5677 (1996).
Rice et al. “Genetic Evidence for Two Distinct Transactivation Functions of TheHerpes simplexVirus α Protein ICP27” J. of Virol. 64:1704-1715 (1990).
Salio et al. “Inhibition of Dendritic Cell Maturation byHerpes simplexVirus” Eur. J. Immunol. 29:3245-3253 (1999).
Sallusto et al. “Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-Stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α” J. Exp. Med. 179:1109-1118 (1994).
Samaniego et al. “Functional Interactions BetweenHerpes simplexVirus Immediate-Early Proteins During Infection: Gene Expression as a Consequence of ICP27 and Different Domains of ICP4” J. of Virol. 69:5705-5715 (1995).
Smiley et al. “Truncation of the C-Terminal Acidic Transcriptional Activation Domain ofHerpes simplexVirus VP16 Produces a Phenotype Similar To That of The in1814 Linker Insertion Mutation” J. of Virol. 71:6191-6193 (1997).
Smith et al. “Evidence That TheHerpes simplexVirus Immdiate Early Protein ICP27 Acts Post-Transcriptionally During Infection to Regulate Gene Expression” Virology 186:74-66 (1992).
Strelow et al. J. Virol. 69:6779-6786 (1995).
Thomas et al. “Herpes simplexVirus Latency-Associated Transcript Encodes a Protein Which Early Greatly Enhances Virus Growth, Can Compensate for Deficiencies in Immediate-Early Gene Expression, and Is Likely To Function During Reactivation from Virus Latency” J. of Virol. 73:6618-6625 (1999).
Thompson et al. “Herpes simplexVirus Neurovirulence and Productive Infection of Neural Cells Is Associated with a Function Which Maps Between 0.82 and 0.832 Map Units on the HSV Genome” Virology 172:435-450 (1989).
Wagstaff et al. “Gene Transfer Using a Disabled Herpes Virus Vector Containing the EMCV IRES allows Multiple Gene ExpressionIn VitroandIn Vivo” GeneTherapy 5:1566-1570 (1998).
Walker et al. Vaccine 16:1-5 (1998).
Walker et al. Vaccine 16:6-8 (1998).
Zitvogel et al. “Therapy of Murine Tumors with Tumor Peptide-Pulsed Dendritic Cells: Dependence on T Cells, B7 Costimulation, and T Helper Cell 1-Associated Cytokines” J. Exp. Med. 183:87-97 (1996).
Ace et al. “Construction and Characterization of aHerpes simplexVirus Type 1 Mutant Unable To Transinduce Immediate-Early Gene Expression” J. of Virol. 63:2260-2269 (1989).
Aicher et al. “Successful Retroviral Mediated Transduction of a Reporter Gene in Human Dendritic Cells: Feasibility of Therapy with Gene-Modified Antigen Presenting Cells” Experimental Hematology 25:39-44 (1997).
Arthur et al. “A Comparison of Gene Transfer Methods in Human Dendritic Cells” Cancer Gene Therapy 4:17-25 (1997).
Caux et al. “GM-CSF and TNF-α Cooperate in The Generation of Dendritic Langerhans Cells” Nature 360:258-261 (1992).
Celluzzi et al. “Peptide-Pulsed Dendritic Cells Induce Antigen-Specific, CTL-Mediated Protective Tumor Immunity” J. Exp. Med. 183:283-287 (1996).
Chou et al. “Differential Response of Human Cells To Deletions and Stop Codons in the γ134.5 Gene ofHerpes simplexVirus” J. of Virol. 68:8304-8311 (1994).
Chou et al. “The γ134.5 Gene ofHerpes simplexVirus 1 Precludes Neuroblastoma Cells from Triggering Total Shutoff of Protein Synthesis Characteristics of Programmed Cell Death in Neuronal Cells” Proc. Natl. Acad. Sci. 89:3266-3270 (1992).
Coffin et al. “Herpes simplexVirus-Based Vectors” Gene Manipulation of the Nervous System, Chapter 6, pp. 100-114 (1996).
Coffin et al. “Gene Delivery to the Central and Peripheral Nervous Systems of Mice Using HSV1 ICP34.5 Deletion Mutant Vectors” Gene Therapy 3:886-891 (1996).
Coffin et al. “Pure Populations of Transduced Primary Human Cells Can Be Produced Using GFP Expressing Herpes Virus Vectors and Flow Cytometry” Gene Therapy 5:718-722 (1998).
DeLuca et al. “Isolation and Characterization of Deletion Mutants ofHerpes simplexVirus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4” J. of Virol. 56:558-570 (1989).
Dilloo et al. “A Novel Herpes Vector for the High-Efficiency Transduction of Normal and Malignant Human Hematopoietic Cells” Blood 89:119-127 (1997).
Geiss et al. J. Virol. 74:111137-11144 (2000).
Gendler et al. “Molecular Cloning and Expression of Human-Tumor-Associated Polymorphic Epithelial Mucin” J. of Biol. Chem. 265:15286-15293 (1990).
Girolomoni et al. “Dendritic Cells Hold Promise for Immunotherapy” Immunology Today 18:103-104 (1997).
Goldsmith et al. “Infected Cell Protein (ICP)47 EnhancesHerpes simplexVirus Neurovirulence by Blocking the CD8 T Cell Response” J. Exp. Med. 187:341-348 (1998).
Gossen et al. “Tight Control of Gene Expression in Mammalian Cells by Tetracycline-Responsive Promoters” Proc. Natl. Acad. Sci. 89:5547-5551 (1992).
Biovex Limited
Mosher Mary E.
Nixon & Vanderhye P.C.
LandOfFree
Herpes viruses for immune modulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpes viruses for immune modulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpes viruses for immune modulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3677652